A new study indicates that the drug FTY720 prevents disease in a mouse model of two leukemias -- blast crisis chronic myeloid leukemia and acute lymphocytic leukemia -- caused by the cancer protein ...

FTY720, a novel oral therapy in development for MS, shows sustained benefits for the majority of patients after three years of treatment Phase II study extension shows 68-73% of patients with multiple ...

You have full access to this article via your institution. In conclusion, we show that SET forms an inhibitory complex with PP2Ac in AML, impairing the activity of PP2A, and that the whole structure ...

‡ Relapse rate over 2 years. im.: Intramuscular; iv.: Intravenous; NA: Not available in pivotal clinical trials; p.o.: By mouth; sc.: Subcutaneous. Data taken from ...

Alexandria, VA, USA – A study aiming to deliver Fingolimod (FTY720) loaded polymer scaffolds to enhance oral wound healing by modulating pro-regenerative immune cell migration associated with improved ...

A new treatment kills ovarian cancer cells in a way that can break the resistance mechanism -- even in those resistant to cisplatin. Researchers found the drug (FTY720) had a potent effect in human ...

Impact of AKT inhibitor MK-2206 on erlotinib resistance in non-small cell lung cancer (NSCLC). This is an ASCO Meeting Abstract from the 2011 ASCO Annual Meeting I. This abstract does not include a ...

FREEDOMS study shows FTY720 reduced relapse rates by 54-60% compared to placebo, and disability progression by 30-32%[1] Results build on Phase III TRANSFORMS one-year study showing FTY720 reduced ...

Data presented at the American Academy of Neurology show annual relapse rates reduced by 62% in newly treated patients Relapse rates reduced by 44% in previously treated patients New extension data ...

We randomly assigned 281 patients to receive oral fingolimod, at a dose of 1.25 mg or 5.0 mg, or a placebo once daily, and we followed these patients for 6 months with magnetic resonance imaging (MRI) ...